Laidlaw initiates Aeon Biopharma stock coverage with buy rating

Laidlaw initiated AEON Biopharma with a Buy rating and a $1.80 price target versus the stock's $0.24 trading price, implying substantial upside potential. The bullish thesis rests on analytical data indicating its ABP-450 botulinum-toxin biosimilar is structurally identical to Botox and expected progress after an FDA Type 2b meeting. Risks remain significant: AEON shares are down 78% year-to-date, the company is rapidly consuming cash, and H.C. Wainwright recently cut its target to $1.20 from $5.00 while retaining a Buy rating.

Analysis

AEON is effectively a financing-and-regulatory optionality instrument, not a conventional valuation opportunity. A favorable FDA interaction can re-rate a micro-cap rapidly, but analytical similarity alone does not establish interchangeability, labeling scope, manufacturing comparability, commercial access, or a viable launch balance sheet. The key near-term variable is cash runway through the next FDA-defined milestone; absent non-dilutive capital or a strategic partner, any price strength is likely to be met by equity issuance and warrant overhang.

The more important competitive implication is that a successful full-label Botox biosimilar would pressure the high-margin therapeutic toxin franchise of AbbVie (ABBV), but that outcome is a multi-year possibility rather than an earnings issue for ABBV in the next 12-18 months. AEON's potential advantage is payer-driven substitution in therapeutic indications, where price sensitivity is greater than aesthetics; its disadvantage is that physician training, distribution, and formulation confidence create switching friction. Consensus appears to be anchoring on the nominal analyst target rather than probability-weighting regulatory execution, dilution, and commercialization costs, making the expected-value setup less attractive than the headline upside implies.

Key Decisions for Investors

• No core long recommendation before disclosure of cash runway, fully diluted share count, and the FDA's written feedback or a clearly defined next regulatory milestone. Treat any pre-catalyst move as speculative; lack of a financing solution within the next 1-3 months would invalidate a bullish setup.
• For a catalyst sleeve only, consider a small AEON position after a post-meeting filing confirms a streamlined development path and the stock holds above the announcement-day volume-weighted average price for 2-3 sessions. Size for a potential total loss; take partial profits into a 75-100% move because financing risk can overwhelm regulatory momentum.
• Monitor ABBV only as a 6-18 month watch item rather than a short: meaningful downside requires evidence that AEON can fund development, secure approval, and win therapeutic reimbursement. ABBV's toxin exposure is unlikely to be materially impaired by a single early-stage challenger in the current earnings horizon.
• Set an alert for an at-the-market program, convertible issuance, reverse split, or material increase in authorized shares. Any of these would shift the risk/reward against AEON regardless of positive analytical or meeting commentary.